Foundations
Cyclic Peptides Explained: Head-to-Tail, Disulfide and Stapled Rings
EW
· 10 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
A cyclic peptide is one whose chain is closed into a ring instead of ending in a free amine and a free acid. The ring can be made backbone to backbone, between two side chains, between a side chain and a terminus, or through a disulfide bridge between cysteines. Closing the ring removes the chain ends that exopeptidases attack and restricts the molecule to fewer shapes, which usually raises both stability and binding affinity. Over forty cyclic peptide drugs are in clinical use.

How is a peptide cyclised?
Four topologies cover nearly everything, and the names describe which atoms are joined.
| Type | What is joined | Notes |
|---|---|---|
| Head-to-tail (homodetic) | The N-terminal amine to the C-terminal acid | No termini left at all; the ring is pure backbone |
| Side-chain to side-chain | Two side chains, most often a lysine amine to an aspartate or glutamate acid | A lactam bridge; the backbone termini remain free |
| Side-chain to terminus | A side chain to the opposite end of the backbone | Used when a terminus must stay free for activity |
| Disulfide | Two cysteine thiols, oxidised to a cystine bridge | Reversible — reducing conditions open it again |
Góngora-Benítez and colleagues' review of disulfide bonds in therapeutic peptides covers that last class in depth, including the problem of making the right bridge when a molecule contains several cysteines (PMID 24446748). The redox chemistry, scrambling and verification are the subject of disulfide bonds in peptides.
Two refinements sit on top of this. A bicyclic peptide closes two rings, often by joining three cysteines to a small trivalent scaffold, giving a more rigid structure with more contact surface. A stapled peptide, discussed below, uses a synthetic hydrocarbon bridge rather than a natural linkage.
The synthesis itself is the awkward part. Macrocyclisation competes with the same reaction happening between two different molecules, so the closing step is usually run dilute to favour the intramolecular route, and yields fall as ring strain rises. The linear assembly that precedes it is ordinary solid-phase chemistry — see solid-phase peptide synthesis.
Why does cyclisation change stability?
Two mechanisms, and they are independent.
The first is the removal of chain ends. Aminopeptidases and carboxypeptidases work inwards from a free terminus; a head-to-tail cycle has neither, so that whole route of degradation closes. Endopeptidases can still cut an internal bond, but a single cut in a ring produces a linear peptide rather than two fragments, and the molecule has to be cut twice to be taken apart.
The second is conformational restriction. A linear peptide samples an enormous number of shapes; a ring samples far fewer. Fewer accessible conformations means a lower entropic cost when the molecule adopts the one its target recognises, which usually shows up as higher affinity. It also means fewer shapes that fit into a protease active site. Driggers and colleagues make the general case for macrocycles on exactly these grounds — diverse functionality and stereochemical complexity in a conformationally pre-organised ring, giving high affinity and selectivity while retaining enough bioavailability to reach intracellular targets (PMID 18591981).
What cyclisation does not do is make a peptide chemically inert. Oxidation of methionine, deamidation of asparagine and hydrolysis under harsh conditions all proceed in a ring as they do in a chain; the routes are catalogued in peptide degradation pathways.
Does cyclisation improve membrane permeability?
Sometimes, and the mechanism is more subtle than "smaller and rounder".
The barrier for a peptide crossing a membrane is largely the cost of stripping water from its polar backbone amides. A cyclic peptide can pay less of that cost if it can fold so that its amide NH groups hydrogen-bond to each other internally, hiding the polarity from the lipid. Backbone N-methylation helps by removing those donors altogether.
White and colleagues tested this systematically. Using on-resin N-methylation of cyclic peptides, they generated variants and found the degree and position of methylation depended on backbone stereochemistry, implying that conformation dictates where the reaction happens. One of the most permeable compounds, a cyclic hexapeptide of 755 Da with three N-methyl groups, showed bioavailability of 28% in rat (PMID 21946276). That is a striking number for a peptide, and it is a rat number for one designed scaffold — not a property of cyclic peptides in general.
The natural-product precedent is cyclosporine, a fungal cyclic peptide whose backbone carries several N-methylated amides and which is absorbed from the gut and acts inside cells. Borel's account of its discovery and early pharmacological development describes how unexpected that profile was at the time (PMID 12422576).
Which approved medicines are cyclic peptides?
Many, and most came from nature rather than from design. Zorzi, Deyle and Heinis counted over forty cyclic peptide drugs in clinical use, with roughly one new one reaching the market per year, and noted that the large majority derive from natural products such as antimicrobials and human peptide hormones (PMID 28249193).
Four examples show the different ring types doing different work.
Cyclosporine is a head-to-tail cyclic peptide of fungal origin, in use as an immunosuppressant since the early 1980s. Borel's history sets out its development (PMID 12422576).
Octreotide is a disulfide-bridged octapeptide analogue of somatostatin. Bauer and colleagues reported it as highly resistant to degradation by pure enzymes and tissue homogenates, at least twenty times more active than somatostatin in rat and rhesus monkey depending on the test system, and much longer acting (PMID 6128648). Its ring is closed by a cystine bridge, and it also carries two D-residues — see D-amino acids in peptides. Lamberts and colleagues' review in the New England Journal of Medicine covers its clinical use (PMID 8532003).
Oxytocin is a nonapeptide closed by a single disulfide bridge between two cysteines, leaving a short tail outside the ring. It is among the oldest peptide medicines, and its ring is a disulfide rather than an amide, so it is a cycle only as long as it stays oxidised.
Bremelanotide is a cyclic heptapeptide melanocortin-receptor agonist, approved in the United States in 2019 for one narrow indication in premenopausal women and not authorised in Canada. Dhillon and Keam summarise the development record (PMID 31429064). The gap between that approved product and research material sold under the name PT-141 is the whole subject of the PT-141 research page.
Canadian marketing authorisations can be checked directly in Health Canada's Drug Product Database, which is the authoritative record of what is licensed for sale here. Nothing sold for laboratory research is an approved drug product, whatever the molecule.
What is a stapled peptide?
A stapled peptide is a linear sequence locked into a helix by a synthetic hydrocarbon bridge between two residues positioned one or two turns apart. The bridge is installed by ring-closing metathesis between unnatural amino acids bearing alkene side chains. The result is technically a macrocycle, though the ring runs through the side chains and the backbone stays open.
Walensky and colleagues reported the approach on a BH3 helix from the apoptosis regulator BID, showing the stapled helix bound its partner proteins and was active in a mouse leukaemia model (PMID 15353804). Kim and colleagues later published a general synthetic protocol for all-hydrocarbon stapled helices (PMID 21637196).
The motivation is specific. Short helical peptides lose their helix the moment they leave the protein they came from, and an unstructured chain binds poorly and is degraded fast. A staple restores the secondary structure and, with it, both affinity and resistance to proteolysis. The class has been studied extensively for protein-protein interfaces that small molecules cannot reach; results in the clinic have been mixed, and no stapled peptide is a widely approved medicine.
What does a ring mean for analysis?
A cyclic peptide analyses differently, and a laboratory needs to know the topology before it starts.
- Mass. Head-to-tail cyclisation releases water, so the intact mass is 18 Da below the linear sequence sum. A disulfide bridge removes two hydrogens, about 2 Da. Reading a cyclic peptide against a linear theoretical mass gives a mismatch that means nothing.
- Fragmentation. A ring has no termini, so there is no ordered b/y series to read. The ion must be opened first, and it can open at any amide, giving overlapping series. Protonated cyclic peptides also show the scrambling behaviour discussed in peptide sequencing by tandem mass spectrometry — which is itself evidence that linear fragment ions cyclise in the gas phase.
- Regiochemistry. For a peptide with several cysteines, the mass is the same whichever pairs are bridged. Establishing which is a separate determination.
- Chromatography. A cyclic form and its linear precursor are usually well separated by reverse-phase HPLC, which makes incomplete cyclisation one of the easier synthesis problems to see on a chromatogram — see HPLC and LC-MS testing.
None of these is exotic, but a certificate that does not state the topology it assumed has not told you what it measured. The general limits are in what a certificate of analysis establishes. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Are cyclic peptides always more stable than linear ones? More resistant to exopeptidases, nearly always, because the chain ends those enzymes need are gone. Not necessarily more stable overall: internal cleavage by endopeptidases still happens, and the chemical degradation routes — oxidation, deamidation, hydrolysis at harsh pH — are unaffected by whether the chain is closed.
Is a disulfide-bridged peptide a cyclic peptide? By topology, yes: the bridge closes a ring. It is a conditional ring, though. Disulfides are reduced in the cytosol and by common laboratory reductants, which reopens the structure, whereas an amide or hydrocarbon linkage does not come apart under those conditions.
Why are so many cyclic peptide drugs natural products? Because microorganisms evolved them as chemical weapons, under selection for exactly the properties drug developers want: resistance to the proteases of competitors and prey, and tight binding to a specific target. Synthetic discovery methods have only recently begun producing cyclic peptides against targets for which nature offers no starting point.
Can a cyclic peptide be taken by mouth? A few can, and cyclosporine is the classic case, but it is the exception rather than the rule and depends on a particular combination of ring size, backbone N-methylation and the ability to hide polar groups internally. Most cyclic peptides, like most peptides, are poorly absorbed from the gut.
How do you confirm the ring actually closed? By mass first — cyclisation changes the intact mass by a defined amount — and by chromatography, since the cyclic product usually separates cleanly from its linear precursor. For a molecule with multiple possible linkages, confirming which atoms are joined requires selective cleavage and fragment analysis, not an intact mass.
Selected Research References
- Zorzi A, Deyle K, Heinis C. Cyclic peptide therapeutics: past, present and future. Current Opinion in Chemical Biology. 2017;38:24-29. pubmed.ncbi.nlm.nih.gov/28249193
- Driggers EM, Hale SP, Lee J, et al. The exploration of macrocycles for drug discovery: an underexploited structural class. Nature Reviews Drug Discovery. 2008;7(7):608-624. pubmed.ncbi.nlm.nih.gov/18591981
- White TR, Renzelman CM, Rand AC, et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nature Chemical Biology. 2011;7(11):810-817. pubmed.ncbi.nlm.nih.gov/21946276
- Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wiener Klinische Wochenschrift. 2002;114(12):433-437. pubmed.ncbi.nlm.nih.gov/12422576
- Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences. 1982;31(11):1133-1140. pubmed.ncbi.nlm.nih.gov/6128648
- Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. New England Journal of Medicine. 1996;334(4):246-254. pubmed.ncbi.nlm.nih.gov/8532003
- Góngora-Benítez M, Tulla-Puche J, Albericio F. Multifaceted roles of disulfide bonds: peptides as therapeutics. Chemical Reviews. 2014;114(2):901-926. pubmed.ncbi.nlm.nih.gov/24446748
- Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305(5689):1466-1470. pubmed.ncbi.nlm.nih.gov/15353804
- Kim YW, Grossmann TN, Verdine GL. Synthesis of all-hydrocarbon stapled alpha-helical peptides by ring-closing olefin metathesis. Nature Protocols. 2011;6(6):761-771. pubmed.ncbi.nlm.nih.gov/21637196
- Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606. pubmed.ncbi.nlm.nih.gov/31429064
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
